PFSA News

Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Profusa Announces Third Quarter Business and Financial Highlights

Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026

Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe

Profusa Invests Additional $1 Million in Digital Treasury Assets

Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base